动物模型中抗骨吸收治疗期间根尖通畅对颌骨坏死风险的影响
研究评估抗骨吸收药物唑来膦酸或地舒单抗治疗大鼠行根尖通畅是否增加颌骨坏死风险,42只大鼠分6组,药物腹腔注射4周后行牙髓治疗,21天后处死行大体、显微CT和组织病理学评估。所有动物均无骨暴露或坏死征象,仅有唑来膦酸联合根尖通畅组出现不能关联坏死的显微CT骨微结构变化。
要点
- 唑来膦酸或地舒单抗治疗大鼠行根尖通畅未导致颌骨坏死。
- 所有动物均无骨暴露、皮质骨破坏、骨膜反应或死骨形成。
- 唑来膦酸联合根尖通畅组骨体积百分比和骨密度低于唑来膦酸组。
核心结论
- 在唑来膦酸或地舒单抗治疗的大鼠中,根尖通畅未导致颌骨坏死,仅唑来膦酸治疗动物出现不能关联颌骨坏死的显微CT骨微结构变化。
研究设计与样本
- 动物实验,42只雄性Wistar大鼠按用药和是否行根尖通畅分6组(每组n=7):唑来膦酸组、唑来膦酸-根尖通畅组、地舒单抗组、地舒单抗-根尖通畅组、对照组、对照-根尖通畅组。
- 唑来膦酸组和唑来膦酸-根尖通畅组腹腔注射唑来膦酸0.125 mg/kg,地舒单抗组和地舒单抗-根尖通畅组腹腔注射地舒单抗0.25 mg/kg,均每周两次持续4周。
- 给药结束1周后行左下第一磨牙牙髓治疗,根尖通畅组用10号K锉在电子根尖定位仪辅助下超出根尖孔,其他组锉插入至距根尖短于定位仪测定值处。
- 术后21天处死动物,行大体观察、显微CT和组织病理学评估是否存在颌骨坏死;统计采用频率统计和GLM多因素方差分析及Tukey检验,显著性水平p < .05。
主要发现
- 所有动物均未出现骨暴露或药物相关性颌骨坏死的其他临床体征,显微CT和组织病理学评估未见皮质骨破坏、骨膜反应或死骨形成。
- 药物对部分显微CT参数有显著影响(p < .05),而根尖通畅单独无显著影响(p > .05)。
- 药物与根尖通畅交互作用中,唑来膦酸-根尖通畅组骨体积百分比和骨密度显著低于唑来膦酸组,地舒单抗组未观察到该趋势(p < .05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To evaluate whether performing apical patency (AP) poses a risk for the development of osteonecrosis in rats treated with the antiresorptive drugs Zoledronic Acid (ZA) or Denosumab (DMAB). METHODOLOGY: Forty-two male Wistar rats were divided into six groups according to the medication administered and whether apical patency was performed (n = 7): ZA, ZA-AP, DMAB, DMAB-AP, and the control groups CON and CON-AP. The ZA and ZA-AP groups received 0.125 mg/kg of ZA, while the DMAB and DMAB-AP groups received 0.25 mg/kg of DMAB, both administered via intraperitoneal injection twice a week for 4 weeks. One week after completing drug administration, endodontic access was performed on the distal occlusal fossa of the lower left first molars in all animals. AP was carried out in the distal canal of the ZA-AP, DMAB-AP, and CON-AP groups using a size 10 K-file with the aid of an electronic apex locator, extending beyond the apical foramen. In the other groups, the file was inserted up short of apex as determined by electronic apex locator measurement. Coronal sealing was performed and after 21 days, the animals were euthanized, and visual analysis, micro-CT, and histopathological assessments were conducted to evaluate the presence or absence of osteonecrosis. Statistical analysis was performed using frequency statistics and a GLM multivariate ANOVA model followed by Tukey's test with significance at p < .05. RESULTS: None of the animals exhibited bone exposure or other clinical signs associated with medication-related osteonecrosis of the jaw. No cortical bone destruction, periosteal reaction, or bone sequestration was observed in the micro-CT or histopathological assessments. Medication significantly influenced some micro-CT parameters (p < .05), while the apical patency alone did not (p > .05). When interacting with medication*apical patency, the ZA-AP group showed a significantly lower percentage of bone volume and bone mineral density compared to the ZA group, a tendency not observed in DMAB groups (p < .05). CONCLUSIONS: Apical patency in rats treated with zoledronic acid or denosumab did not cause osteonecrosis of the jaw, only micro-CT changes in bone microarchitecture that cannot be linked to osteonecrosis in zoledronic acid treated animals.
引用
- Lopes CF, Pinto KP, Ferreira CMA, et al. The risk of osteonecrosis after apical patency during antiresorptive therapy in an animal model. Int Endod J. 2025. PMID: 39904856. doi:10.1111/iej.14207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。